-
MedinCell Announces Fiscal Year Consolidated Results
MedinCell Announces Fiscal Year Consolidated Results
Share
MONTPELLIER, France--(BUSINESS WIRE)--Strong consolidated financial position as at March 31, 2020 and strengthened since year-end
- 12.4 M€ in cash and cash equivalents
- 3.6 M€ of risk-free financial assets (0.4 M€ current + 3.3 M€ non-current)
- 10.9 M€ of additional non-dilutive financing (PGE) -Post-closing
- 3.1 M€ of CIR collected in May 2020 - Post closing
- 5.0 M€ to be received from the EIB under conditions
Consolidated financial results:
- Income from ordinary activities: 6.O M€ (+48% compared to the previous year)
- Cash consumption linked to the activity: 12.5 M€ (in line with expectations)
Evolution of the product portfolio in line with expectations
- Progress in clinical development: Phase 3 of mdc-IRM (antipsychotic), led and funded by Teva Pharmaceuticals and mdc-CWM (post-operative pain and inflammation), funded by AIC
- A third product in clinical development: start of Phase 1 of the mdc-TJK (antipsychotic) product led and financed by Teva Pharmaceuticals
- Two new products in regulatory preclinical studies: mdc-ANG (antipsychotic) and mdc-WWM (contraception), the latter benefiting from a new four-year 19 M$ grant from the Bill & Melinda Gates Foundation
- Three programs close to formulation selection that paves the way for preclinical development: mdc-GRT (organ transplantation), mdc-NVA (pain) and mdc-KPT (animal health)
-
New program launches:
- mdc-STM: formulation of a 3-month active injectable of Ivermectin to neutralize the vector of malaria transmission, the program received a 6.4 M$ grant over three years from Unitaid
- mdc-STG: new internal program in formulation
- Feasibility study of an injectable long-acting HIV prevention treatment (PrEP) funded by the Gates Foundation
Significant post-closing events related to the product portfolio:
- Recruitment completed for the mdc-IRM Phase 3 clinical study, interim analysis expected before the end of 2020
- Completion of the mdc-CWM Phase 2 clinical study, Phase 3 is scheduled to begin by the end of 2020
- Launch of a research program for Covid-19 prevention (prophylaxis)
Access the complete Press release
Contacts
MedinCell
David Heuzé
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86
NewCap
Louis-Victor Delouvrier
Relations investisseurs
medincell@newcap.eu
+33 (0)1 44 71 98 53
NewCap
Nicolas Merigeau
Relations médias
medincell@newcap.eu
+33 (0)1 44 71 94 98
More News From MedinCell
EIB Waives its Right to Cash Settlement on Medincell Warrants
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that the European Investment Bank (EIB) has waived on March 26, 2026 the put option attached to approximately 780,000 warrants granted in connection with the €40 million financing agreement executed in 2022. As a result of this waiver and the resulting new terms applicable to t...
Medincell Announces Successful c. €48 Million Private Placement
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, Australia, South Africa, Canada or Japan Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the "Company"), today announced the successful pricing of its Private Placement (as defined below) for a total amoun...
Medincell Launches a Private Placement for International Institutional Investors
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the “Company”), today announced the launch of a private placement of approximately 6% of the Company’s share capital...
